Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiopoietin-like 3 protein (ANGPTL3) is a secreted glycoprotein primarily expressed in the liver. It plays a central role in lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL), thereby modulating triglyceride, LDL-C, and HDL-C levels. It is also involved in angiogenesis through interactions with integrins on endothelial cells. ANGPTL3 is a promising molecular target for reducing CHD risk.
Inhibition of LPL and EL, leading to increased plasma triglyceride, LDL-C, and HDL-C levels. Also interacts with integrins to promote cell adhesion and migration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Angiopoietin-like 3 protein (ANGPTL3).